Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma

Cancer
David NanusJanice Dutcher

Abstract

Immunotherapy is generally ineffective in patients with sarcomatoid renal cell carcinoma (RCC) and in patients with rapidly progressive metastatic or locally recurrent disease, with a median time to progression of approximately 2 months and a median survival of 4-7 months. Gemcitabine-based regimens have modest antitumor activity, whereas doxorubicin is often used to treat sarcomatoid RCC. Based on the antitumor activity of doxorubicin and gemcitabine in collecting duct carcinoma of the kidney, the authors used this combination to treat selected patients with sarcomatoid or rapidly progressing RCC. Eighteen patients (11 males and 7 females; median age, 53 years; range, 31-81 years) with RCC (56% sarcomatoid; 44% other) were treated at 2 institutions in a collaborative study that was not institutional review board reviewed. Seven patients received previous treatment with interferon or interleukin-2. Sites of metastases included the lung, soft tissue, bone, liver, and brain with 88% of patients having > or = 3 sites of disease. Treatment consisted of doxorubicin (50 mg/m2) and gemcitabine (1500 or 2000 mg/m2) every 2-3 weeks with granulocyte-colony-stimulating factor support. A median of 5 courses was administered (range, 2-12 cy...Continue Reading

References

Sep 15, 1987·Cancer·A SellaM L Samuels
Apr 1, 1993·Annals of Oncology : Official Journal of the European Society for Medical Oncology·W C MertensD Wong
Jan 1, 1996·Cancer Chemotherapy and Pharmacology·P H De MulderJ Blatter
Mar 18, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·T CangianoA Belldegrun
Jan 27, 2000·The Journal of Urology·R J Motzer, P Russo
Feb 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P M DoddD F Bajorin
Jun 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B I RiniW M Stadler
Feb 27, 2001·The American Journal of Surgical Pathology·M de Peralta-VenturinaM B Amin
Apr 13, 2001·Annals of Oncology : Official Journal of the European Society for Medical Oncology·N BangaloreP Bhargava
Dec 18, 2001·The Journal of Urology·Badar M MianLouis L Pisters
Feb 28, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C M GeorgeW M Stadler
Apr 12, 2002·BJU International·M GrabowskiA Sikorski
Apr 30, 2003·The American Journal of Surgical Pathology·John C ChevilleMichael L Blute
Apr 30, 2003·International Journal of Clinical Oncology·Senji HoshiYoichi Arai
May 2, 2003·Seminars in Oncology·Jacek Jassem
Jun 20, 2003·European Urology·Ivar BleumerPeter F A Mulders
Sep 5, 2003·The Urologic Clinics of North America·Matthew I Milowsky, David M Nanus
Sep 23, 2003·The Journal of Urology·Walter M StadlerNicholas J Vogelzang

❮ Previous
Next ❯

Citations

Dec 24, 2005·Der Urologe. Ausg. A·M StaehlerC G Stief
Apr 20, 2006·Der Urologe. Ausg. A·M AutenriethJ E Gschwend
Apr 5, 2005·World Journal of Urology·Karl RohrmannMichael Siebels
May 12, 2011·Medical Oncology·Maria Carmen AresesRafael López López
Jan 5, 2011·Anti-cancer Drugs·Pedro SánchezIgnacio Durán
Apr 5, 2013·Anti-cancer Drugs·Sebastiano ButiFrancesco Massari
Apr 9, 2008·American Journal of Clinical Oncology·Rachel P RiechelmannJennifer J Knox
Dec 4, 2010·American Journal of Clinical Oncology·Ana M MolinaRobert J Motzer
Dec 1, 2006·Nephron. Clinical Practice·Ali VaranMunevver Buyukpamukçu
Dec 29, 2006·Chemotherapy·Satoshi MatsusakaIchiro Wakabayashi
Jun 13, 2012·Journal of Radiology Case Reports·Michael ReiterArthur Clarkson
Mar 8, 2012·Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada·Mas JewettJ Willacy
Jan 17, 2009·Medical Oncology·Antonio Romo de Vivar ChavezMichael T Lotze
Feb 25, 2014·Clinical Genitourinary Cancer·Victoria KuneneEmilio Porfiri
Sep 3, 2014·Journal of Cancer Research and Clinical Oncology·Yi YanLin Qi
Feb 12, 2013·Journal of Cancer Research and Clinical Oncology·Inkeun ParkHanjong Ahn
Jun 9, 2007·Expert Review of Anticancer Therapy·Jin-Young ParkRobert H Weiss
Jun 29, 2011·Expert Review of Anticancer Therapy·Lance C PagliaroEric Jonasch
Mar 28, 2008·Expert Review of Anticancer Therapy·Jeffrey A Sosman
Sep 24, 2008·Expert Opinion on Investigational Drugs·Bhanu K Vakkalanka, Ronald M Bukowski
Feb 13, 2016·Proceedings of the National Academy of Sciences of the United States of America·Mark BiBrian Shuch
Nov 2, 2011·Clinical Imaging·Andrew B RosenkrantzJonathan Melamed
Jul 19, 2011·Hematology/oncology Clinics of North America·Simon ChowdhuryNizar M Tannir
Jul 7, 2009·Urologic Oncology·Michele BassoCarlo Barone
Nov 11, 2008·The Urologic Clinics of North America·Glenn S Kroog, Robert J Motzer
May 30, 2006·Clinical Genitourinary Cancer·Kevin A DavidDavid M Nanus
Sep 4, 2007·The Lancet Oncology·Hashim Uddin AhmedImran Mushtaq
Mar 3, 2007·Cancer Treatment Reviews·Eric C NelsonPrimo N Lara
Sep 1, 2015·Critical Reviews in Oncology/hematology·E DiamondD M Nanus
May 10, 2005·BJU International·Michael StaehlerMichael Siebels
Apr 24, 2008·BJU International·Sabina SignorettiMichael Atkins
Feb 5, 2008·BJU International·Andres J SchraderRainer Hofmann
Dec 21, 2005·Pediatric Blood & Cancer·James I Geller, Jeffrey S Dome

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.